In this PharmaPhorum article, authors Lev Gerlovin and Pascale Diesel conducted an analysis of recent activity in the biotechnology sector to better understand deal-making trends related to cell and gene therapies. They reviewed more than 30 mergers, acquisitions, and licensing agreements executed between 2016-2019 and compared them to deals that were executed for the previous generation of breakthrough therapies, including monoclonal antibodies (mAbs).
In this analysis, the authors considered a range of factors including the size of the companies involved, target indications, deal structures, terms such as upfront payments and royalties, and the number and clinical stage of assets included in each deal.
The authors acknowledge the contributions of Súil Collins and Alex David.
Click the link below to read the article.
Ending the HIV epidemic: Ensuring equitable access to innovative HIV treatment and care
While advances in prevention, testing, and treatment have transformed outcomes for many people living with or at risk of HIV, significant inequities continue...